AstraZeneca Reports Five-Year Survival Data for Tagrisso in Early-Stage Lung Cancer

AstraZeneca today presented five-year overall survival data from the Phase 3 ADAURA trial evaluating Tagrisso (osimertinib) as adjuvant therapy in patients with resected EGFR-mutated non-small cell lung cancer. The data showed a 51% reduction in the risk of death with Tagrisso compared to placebo in patients with stage II-IIIA disease.